Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Psychiatry indexChapter sections
Purpose and principlesIndications, selection and cautionsAssessment before treatmentTreatment approachRegimens, contraindications and interactionsComplications, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook10 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Lithium, valproate, carbamazepine and lamotrigine monitoring

Psychiatry · UK scope · Sources checked 7 Sept 2026 · Clinical review pending

RapidFull
!
Withhold suspected lithium toxicity

Vomiting, coarse tremor, ataxia, dysarthria, confusion or reduced consciousness during lithium treatment can indicate toxicity, even when a measured concentration is within the usual target range.

Action: Withhold lithium, obtain an urgent lithium concentration and renal/electrolyte tests, and seek immediate specialist or emergency assessment according to severity; do not wait for a routine twelve-hour sample.

Purpose and principles

Plan drug-specific monitoring for four commonly used mood stabilisers, interpret abnormal results in their clinical context, and recognise toxicity, severe skin reactions and reproductive-safety requirements before harm develops.

Mood stabilisers differ substantially in therapeutic role, elimination and monitoring needs. Lithium is renally cleared and has a narrow therapeutic index. Valproate can injure the liver, pancreas and blood system and carries major reproductive risks. Carbamazepine induces hepatic enzymes, alters other drug concentrations and may cause hyponatraemia or severe skin reactions. Lamotrigine requires a slow titration because excessive initial exposure increases rash risk. A generic annual blood panel cannot substitute for these distinct safeguards.

Start with the indication, current formulation, dose, adherence and responsible prescriber. Establish baseline organ function and pregnancy potential, discuss warning symptoms and provide a written monitoring schedule. Shared care needs explicit ownership of prescribing, blood sampling, result interpretation, missed appointments and urgent advice. The presence of a result in the record is not evidence that anyone has reviewed it or informed the person of a changed plan.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
PsychiatryOriginal SBA

Lithium during gastroenteritis

A patient on long-term lithium develops vomiting, a coarse tremor and difficulty walking after three days of diarrhoea. The next routine trough level is booked for next week. What should happen now?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Psychiatry topics →
Sources and review status7 sources · checked 7 Sept 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.

  • NICE CG185 bipolar recommendationsLithium targets, intervals and mood-stabiliser safeguards.
  • SPS lithium monitoringTimed levels and action for suspected toxicity.
  • SPS carbamazepine monitoring January 2026Sodium schedule, ancestry screening and abnormal results.
  • SPS valproate monitoring August 2026Baseline, stable and bleeding-related surveillance.
  • Lamictal SmPCBipolar titration tables, interactions and restart precautions.
  • MHRA valproate reproductive risksCurrent reproductive-safety measures and counselling.
  • MHRA February 2025 valproate clarificationInitiation requirements and established male treatment.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem ·

For lithium, the trend is more informative than one isolated value. Dehydration, diarrhoea, reduced salt intake, acute kidney injury and interacting drugs can raise exposure rapidly. NSAIDs, ACE inhibitors, angiotensin receptor blockers and diuretics require particular attention. A stable historical dose becomes unsafe when clearance changes. Routine concentrations must be interpreted against dose timing and formulation, whereas suspected toxicity requires an immediate sample and clinical action.

Drug levels have different purposes. Lithium levels guide routine treatment and safety. Valproate, carbamazepine and lamotrigine levels are not universal routine screening tests for a stable psychiatric patient; they can help with suspected toxicity, adherence, loss of response or relevant interactions. A therapeutic laboratory range does not rule out an idiosyncratic rash, pancreatitis, liver injury or symptomatic sodium disturbance. Those diagnoses depend on the clinical syndrome.

Reproductive counselling is a continuing process, not a one-time form. Check whether family plans, contraception or capacity to manage the agreed precautions have changed. Distinguish the licensed bipolar indication and formulation from common off-label practice. Explain what to do if pregnancy is suspected and ensure prompt specialist access, avoiding advice that leaves a person to choose between abrupt cessation and continuing without support.

Key points

  • Lithium samples for routine comparison should be taken twelve hours after the previous dose, with dose and sampling time documented.
  • Check lithium one week after starting or changing dose and weekly until stable; then every three months for the first year.
  • After year one, measure lithium every six months, or at least every three months in higher-risk groups.
  • Lithium renal function, calcium, thyroid function and weight need six-monthly monitoring, with earlier review for deterioration.
  • Valproate baseline monitoring includes weight, full blood count, platelets, liver function and clotting assessment; repeat liver tests periodically during the first six months, then at six months and annually.
  • Lamotrigine requires slow interaction-specific titration, urgent attention to rash and a restart assessment after interruption.
  • Carbamazepine sodium monitoring after initiation is particularly important in renal impairment or with sodium-lowering medicines.
  • All new valproate starts below age 55 need two independent specialists to document the regulatory criteria; established male treatment does not require a retrospective two-specialist review.

Indications, selection and cautions

Neurological lithium warning

A coarse rather than fine tremor, unstable gait, slurred speech, confusion and falls are warning signs requiring an urgent toxicity assessment.

Hypersensitivity pattern

Rash, facial swelling, fever, lymphadenopathy or mucosal involvement may precede severe cutaneous or systemic reactions to anticonvulsant mood stabilisers.

Valproate organ injury

Persistent abdominal pain, vomiting, jaundice, spontaneous bruising or infection symptoms should trigger targeted investigation rather than reassurance from old normal tests.

Carbamazepine sodium effect

Headache, lethargy, confusion or seizure can accompany hyponatraemia, especially after dose changes or addition of a thiazide.

Red flags requiring action

  • A new rash with mucosal lesions, blistering, fever or systemic illness on lamotrigine or carbamazepine needs immediate withdrawal assessment and urgent hospital review.
  • Abdominal pain with vomiting, jaundice, unusual bruising or marked lethargy during valproate treatment can indicate pancreatitis, hepatic injury or blood dyscrasia.
  • Pregnancy or pregnancy planning with a mood stabiliser requires prompt specialist review; unsupervised abrupt cessation can cause severe psychiatric or seizure relapse.

Assessment before treatment

  1. 01
    Lithium baseline assessmentFirst step
    Why
    Identify renal, endocrine, cardiac and pregnancy factors that affect safe initiation.
    Interpretation and limitations
    Check weight or BMI, eGFR, urea and electrolytes including calcium, thyroid function and full blood count; obtain ECG with cardiovascular disease or risk and exclude pregnancy where relevant.
  2. 02
    Timed lithium concentration
    Why
    Guide the dose using a comparable trough measurement.
    Interpretation and limitations
    For a person starting lithium NICE usually targets 0.6–0.8 mmol/L; selected relapse or persistent-symptom cases may trial 0.8–1.0 mmol/L for at least six months under closer monitoring.
  3. 03
    Valproate safety bloods
    Why
    Assess liver function and haematological or coagulation vulnerability.
    Interpretation and limitations
    Obtain baseline FBC, platelets, clotting screen and LFTs; abnormal bleeding or hepatic dysfunction requires urgent clinical interpretation rather than adjustment from a valproate level alone.
  4. 04
    Carbamazepine baseline and ancestry assessment
    Why
    Identify blood, liver, sodium and genetically increased skin-reaction risks.
    Interpretation and limitations
    Measure FBC, LFTs, electrolytes and sodium; screen HLA-B*1502 in Han Chinese or Thai ancestry and consider other at-risk Asian groups before exposure.

Treatment approach

01Starting safelyAgree medicine-specific surveillanceFirst stepA mood stabiliser is being initiated or prescribing responsibility is transferring.+
  1. 1Confirm the psychiatric indication, product, contraindications, interactions and reproductive precautions before issuing the medicine.
  2. 2Record baseline tests and an exact schedule for early and continuing monitoring with a named result reviewer.
  3. 3Provide warning-symptom advice and a contact route for illness, missed doses, pregnancy concerns or unavailable blood testing.
02Lithium illnessAct on altered clearance or toxicityThe person develops dehydration, neurological change or a new interacting prescription.+
  1. 1Assess hydration, observations, renal function, medicines and the timing of the most recent lithium doses.
  2. 2

Regimens, contraindications and interactions

Prevention of predominantly depressive episodes in bipolar I disorder; it is not an acute antimanic regimen.

Lamotrigine without valproate or enzyme inducers

For adult bipolar maintenance titration give 25 mg orally daily in weeks 1–2, 50 mg daily in weeks 3–4, 100 mg daily in week 5 and usually 200 mg daily from week 6.

Use a different schedule with valproate or enzyme inducers; assess rash urgently. After an interruption exceeding five half-lives, generally restart the appropriate initial titration rather than the maintenance dose; half-life depends on interacting medicines.

The slower licensed adult bipolar schedule accounts for valproate inhibition of lamotrigine metabolism.

Lamotrigine with concomitant valproate

Give 25 mg orally on alternate days in weeks 1–2, 25 mg daily in weeks 3–4, 50 mg daily in week 5 and usually 100 mg daily from week 6.

Do not accelerate to catch up missed doses; a new rash normally requires prompt discontinuation unless clearly unrelated, with urgent assessment for systemic or mucosal features.

Complications, monitoring and follow-up

  • For stable lithium after the first year use at least three-monthly levels in older people, those with interacting medicines or renal/thyroid risk, poor adherence or symptom control, significant sodium/fluid changes, or a last level of 0.8 mmol/L or higher.
  • Check lithium weight or BMI, renal function, electrolytes including calcium and thyroid function every six months; declining eGFR across repeated tests needs closer monitoring and specialist benefit-risk discussion.
  • For valproate check LFTs periodically during the first six months; check weight or BMI, FBC and LFTs at six months and annually. Obtain clotting/FBC before surgery; spontaneous bruising or bleeding requires withholding treatment pending investigation.
  • The January 2026 SPS carbamazepine schedule advises sodium at two weeks then monthly for three months when renal impairment or sodium-lowering medication is present; continue according to need.
  • Stable carbamazepine requires periodic electrolytes, LFTs and vitamin D assessment; routine plasma levels are unnecessary unless there is a specific clinical question.
  • Review lamotrigine adherence, rash and interactions at titration visits; oestrogen-containing contraception and changes to valproate or enzyme inducers

Special situations

Toxicity without an extreme level

Lithium neurotoxicity may occur within an apparently ordinary concentration, particularly in susceptible people; clinical findings take priority over a reassuring number.

Carbamazepine enzyme induction

An isolated modest gamma-glutamyl transferase rise can reflect enzyme induction, whereas clinical liver disease or worsening hepatic function requires withdrawal assessment.

Formulation matters clinically

Lithium preparations are not casually interchangeable; a brand or formulation change needs a level and retitration plan comparable to a treatment change.

Valproate rules differ by circumstance

The two-specialist initiation requirement applies to new patients under 55, while established male patients continue ordinary specialist review and reproductive counselling without that retrospective requirement.

Common pitfalls

  1. 01

    Requesting a routine lithium trough several days later when the patient already has coarse tremor, vomiting and ataxia.

  2. 02

    Copying the lamotrigine monotherapy titration into a prescription that also contains valproate.

  3. 03

    Treating a normal anticonvulsant level as exclusion of severe hypersensitivity, pancreatitis or liver injury.

  4. 04

    Relying on an annual risk form while failing to ask about changing pregnancy or contraception plans.

  5. 05

    Ignoring sodium monitoring after carbamazepine initiation in someone with renal impairment and a diuretic.

Content changes
Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
05
Lamotrigine baseline and interaction review
Why
Choose a titration that reflects altered glucuronidation and organ function.
Interpretation and limitations
Record FBC, electrolytes and LFTs; valproate slows lamotrigine clearance while enzyme inducers accelerate it, so the dose schedule cannot be copied between regimens.
Escalation
Withhold lithium and obtain urgent levels and electrolytes if toxicity is suspected, escalating clinically without awaiting the result.
  • 3After recovery agree restart, dose, interacting-drug management and repeat levels with the specialist team rather than simply restoring the old prescription.
    • 03Non-lithium alarmInvestigate serious anticonvulsant reactionsRash, systemic symptoms, hepatic signs, abdominal pain or significant blood abnormalities appear.+
    1. 1Assess the syndrome promptly and stop a suspected severe cutaneous reaction medicine while arranging urgent specialist care.
    2. 2Request targeted FBC, liver, clotting, renal, sodium or pancreatic investigations according to symptoms and physiological severity.
    3. 3AlternativeDocument the suspected reaction and future prescribing restrictions, while arranging alternative mood or seizure protection as needed.
    can require specialist dose adjustment.